HURA TuHURA Biosciences, Inc./NV

Nasdaq tuhurabio.com


$ 2.29 $ -0.06 (-2.6 %)    

Wednesday, 22-Oct-2025 17:41:28 EDT
QQQ $ 604.27 $ -5.89 (-0.96 %)
DIA $ 464.98 $ -3.44 (-0.73 %)
SPY $ 666.76 $ -3.49 (-0.52 %)
TLT $ 92.19 $ 0.06 (0.07 %)
GLD $ 376.01 $ 0.04 (0.01 %)
$ 2.25
$ 2.31
$ 2.15 x 100
$ 2.30 x 642
$ 2.16 - $ 2.31
$ 1.80 - $ 7.20
244,241
na
3.77M
$ 0.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 10-07-2024 06-30-2024 10-K
6 05-14-2024 03-31-2024 10-Q
7 02-14-2024 12-31-2023 10-Q
8 11-13-2023 09-30-2023 10-Q
9 09-18-2023 06-30-2023 10-K
10 05-11-2023 03-31-2023 10-Q
11 02-14-2023 12-31-2022 10-Q
12 11-09-2022 09-30-2022 10-Q
13 09-27-2022 06-30-2022 10-K
14 05-13-2022 03-31-2022 10-Q
15 02-11-2022 12-31-2021 10-Q
16 11-15-2021 09-30-2021 10-Q
17 09-28-2021 06-30-2021 10-K
18 05-13-2021 03-31-2021 10-Q
19 02-12-2021 12-31-2020 10-Q
20 11-12-2020 09-30-2020 10-Q
21 09-18-2020 06-30-2020 10-K
22 05-13-2020 03-31-2020 10-Q
23 02-13-2020 12-31-2019 10-Q
24 11-13-2019 09-30-2019 10-Q
25 09-09-2019 06-30-2019 10-K
26 05-14-2019 03-31-2019 10-Q
27 02-11-2019 12-31-2018 10-Q
28 11-13-2018 09-30-2018 10-Q
29 09-24-2018 06-30-2018 10-K
30 05-15-2018 03-31-2018 10-Q
31 02-14-2018 12-31-2017 10-Q
32 11-09-2017 09-30-2017 10-Q
33 09-27-2017 06-30-2017 10-K
34 05-12-2017 03-31-2017 10-Q
35 02-10-2017 12-31-2016 10-Q
36 11-10-2016 09-30-2016 10-Q
37 09-13-2016 06-30-2016 10-K
38 05-12-2016 03-31-2016 10-Q
39 02-12-2016 12-31-2015 10-Q
40 11-16-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of ...

Core News & Articles

Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembro...

Core News & Articles

Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients wi...

Core News & Articles

HC Wainwright & Co. analyst Robert Burns reiterates TuHURA Biosciences (NASDAQ:HURA) with a Buy and maintains $12 price ...

Core News & Articles

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of ...

Core News & Articles

Phase 1b/2a trial designed to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda® when administered ...

Core News & Articles

Kineta presents updated clinical data from VISTA-101 trial of KVA12123, demonstrating >90% VISTA receptor occupancy at 1,000mg

Core News & Articles

HC Wainwright & Co. analyst Robert Burns maintains TuHURA Biosciences (NASDAQ:HURA) with a Buy and lowers the price targ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION